𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors

✍ Scribed by B. Schultheis; G. Kummer; M. Zeth; E. Brendel; C. Xia; M. Kornacker; D. Strumberg

Publisher
Springer
Year
2011
Tongue
English
Weight
282 KB
Volume
69
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

Phase 2 study of gemcitabine in combinat
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
✍ Yasuhiro Oki; Barbara Pro; Luis E. Fayad; Jorge Romaguera; Felipe Samaniego; Fre πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 80 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The management of recurrent or refractory Hodgkin lymphoma (HL) remains challenging. The objective of this phase 2 trial was to investigate the activity of gemcitabine in combination with rituximab in patients with recurring or refractory HL. ## METHODS. Patients were

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and